Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032
By GlobeNewswire Published on May 7, 2025, 22:00 IST
New York, USA, May 07, 2025 (GLOBE NEWSWIRE) — Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight
The demand for AI in clinical trials is experiencing strong growth, primarily fueled by the rising global prevalence of chronic illnesses like diabetes, cardiovascular diseases, respiratory conditions, and cancer. This growth is further bolstered by increasing investments and funding dedicated to enhancing drug discovery and development. Additionally, the expanding trend of strategic alliances and partnerships among pharmaceutical, biotechnology, and medical device firms is significantly contributing to the accelerated adoption of AI-driven clinical trial technologies.
DelveInsight's AI in Clinical Trials Market Insights report provides the current and forecast market analysis, individual leading AI in clinical trials companies' market shares, challenges, AI in clinical trials market drivers, barriers, trends, and key market AI in clinical trials companies in the market.
Key Takeaways from the AI in Clinical Trials Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in clinical trials market during the forecast period.
In the product segment of the AI in clinical trials market, the software category had a significant revenue share in 2024.
Notable AI in clinical trials companies such as TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and several others are currently operating in the AI in clinical trials market.
and several others are currently operating in the AI in clinical trials market. In March 2025, Suvoda launched Sofia, an AI-powered assistant designed to streamline clinical trial management. Built to support study teams, Sofia simplifies access to and review of critical trial information by delivering intelligent, real-time insights. This innovation enhances operational efficiency, reduces manual workload, and empowers teams to make faster, data-driven decisions throughout the trial lifecycle.
launched Sofia, an AI-powered assistant designed to streamline clinical trial management. Built to support study teams, Sofia simplifies access to and review of critical trial information by delivering intelligent, real-time insights. This innovation enhances operational efficiency, reduces manual workload, and empowers teams to make faster, data-driven decisions throughout the trial lifecycle. In December 2024, ConcertAI and NeoGenomics announced the launch of CTO-H, a next-generation AI software solution for research analytics, clinical trial design, and operational optimization. CTO-H delivers an unparalleled research data platform, offering unmatched scale, longitudinal patient insights, and deep biomarker data, enabling more precise, efficient, and data-driven clinical development strategies.
announced the launch of CTO-H, a next-generation AI software solution for research analytics, clinical trial design, and operational optimization. CTO-H delivers an unparalleled research data platform, offering unmatched scale, longitudinal patient insights, and deep biomarker data, enabling more precise, efficient, and data-driven clinical development strategies. In June 2024, Lokavant launched Spectrum™, the first AI-driven clinical trial feasibility solution designed to optimize trial performance across the entire clinical development value chain. Spectrum empowers study teams to predict, manage, and optimize trial timelines and costs in real-time.
To read more about the latest highlights related to the AI in clinical trials market, get a snapshot of the key highlights entailed in the Global AI in Clinical Trials Market Report
AI in Clinical Trials Overview
Artificial intelligence (AI) is revolutionizing clinical trials by enhancing efficiency, accuracy, and patient outcomes across the entire trial lifecycle. AI-powered tools enable faster patient recruitment by analyzing electronic health records and identifying eligible candidates based on complex inclusion and exclusion criteria. This targeted approach reduces trial enrollment time and improves diversity among participants. Additionally, AI can optimize trial design by simulating outcomes using real-world data, allowing researchers to refine protocols and predict potential risks, ultimately leading to more robust and reliable results.
Moreover, AI facilitates real-time monitoring and data analysis during trials, enabling early detection of adverse events and anomalies. Machine learning algorithms can process vast amounts of data from wearable devices, lab results, and patient-reported outcomes to identify patterns that might be overlooked by traditional methods. This enhances decision-making and allows for adaptive trial designs, where protocols can be modified in response to interim findings. As regulatory bodies grow more comfortable with AI-driven methodologies, the integration of AI in clinical trials holds the promise of accelerating drug development while ensuring safety and efficacy.
AI in Clinical Trials Market Insights
North America held the largest share of the AI in clinical trials market in 2024. This leading position is driven by several key factors, including the increasing burden of chronic diseases, substantial R&D investments, and a growing volume of clinical trials in the region. The market is also benefiting from the rise in research collaborations and strategic partnerships among pharmaceutical and medical device companies, alongside the continuous development of sophisticated AI technologies.
Major players in the North American market are making significant R&D investments to develop cutting-edge AI tools aimed at streamlining clinical trials. For instance, in October 2022, Phesi introduced its AI-driven Trial Accelerator platform, which enhances clinical trial planning through real-time scenario analysis. Utilizing the world's most comprehensive clinical trial database, this SaaS platform helps optimize patient recruitment, endpoint determination, country selection, and site allocation—boosting trial efficiency and outcomes.
Likewise, in October 2023, H1 launched GenosAI, a generative AI feature integrated into its Trial Landscape platform. GenosAI is designed to improve clinical trial decision-making by enabling pharmaceutical companies to analyze complex data, simplify trial-related queries, and expedite the selection of sites and principal investigators, thereby facilitating quicker and more strategic trial initiations.
As a result, these factors are expected to drive substantial growth in the North American AI in clinical trials market throughout the 2025–2032 forecast period.
To know more about why North America is leading the market growth in the AI in clinical trials market, get a snapshot of the AI in Clinical Trials Market Outlook
AI in Clinical Trials Market Dynamics
The AI in clinical trials market is experiencing significant growth, driven by advancements in artificial intelligence, machine learning, and data analytics. AI technologies are being increasingly adopted to streamline clinical trial processes, such as patient recruitment, data collection, and monitoring. AI-powered tools help researchers identify suitable candidates faster, reducing the time and costs associated with recruitment. Additionally, AI aids in personalized treatment regimens by analyzing large datasets to identify optimal patient profiles and predict outcomes more accurately.
One of the major factors fueling the market's growth is the need for improving efficiency in clinical trials. AI facilitates real-time monitoring of patient health, enabling researchers to detect potential issues early and make data-driven decisions. By automating time-consuming tasks, AI reduces human error, improves trial design, and accelerates the pace of development for new therapies. This increased efficiency is especially critical as the pharmaceutical industry faces growing pressure to bring drugs to market quickly due to competitive pressures and a rising demand for novel treatments.
Another key driver in the AI in clinical trials market is the increasing complexity of modern drug development. With more targeted therapies, such as immunotherapies and gene therapies, clinical trials require sophisticated designs to accommodate diverse patient populations and intricate treatment regimens. AI technologies, including predictive analytics and natural language processing, help streamline this complexity by analyzing vast datasets to uncover meaningful insights. This supports the creation of more robust trial designs and accelerates decision-making processes, ultimately reducing costs.
Despite its advantages, the adoption of AI in clinical trials faces challenges, such as concerns around data privacy, regulatory compliance, and the need for skilled personnel. Healthcare data is highly sensitive, and regulatory bodies are still adapting to ensure AI tools meet the necessary standards for clinical use. Furthermore, while AI can greatly assist in data analysis, the technology still requires human oversight to interpret results and ensure that ethical guidelines are followed. Addressing these challenges will be crucial for widespread AI adoption and for realizing its full potential in clinical trials.
Looking ahead, the AI in clinical trials market is expected to expand further with the integration of more advanced AI capabilities, including deep learning and real-time data integration from wearables and remote monitoring devices. As healthcare systems continue to digitize and AI technologies evolve, their use in clinical trials will likely become more ubiquitous, making trials faster, cheaper, and more effective. The market is poised for continued growth, with AI playing a pivotal role in shaping the future of clinical research.
Get a sneak peek at the AI in clinical trials market dynamics @ AI in Clinical Trials Market Dynamics Analysis Report Metrics Details Coverage Global Study Period 2022–2032 AI in Clinical Trials Market CAGR ~12% AI in Clinical Trials Market Size by 2032 USD 3.3 Billion Key AI in Clinical Trials Companies TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, among others
AI in Clinical Trials Market Assessment AI in Clinical Trials Market Segmentation AI in Clinical Trials Market Segmentation By Product: Software and Services AI in Clinical Trials Market Segmentation By Technology: Machine Learning (ML), Natural Language Processing (NLP), and Others AI in Clinical Trials Market Segmentation By Application: Clinical Trial Design & Optimization, Patient Identification & Recruitment, Site Identification & Trial Monitoring, and Others AI in Clinical Trials Market Segmentation By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others AI in Clinical Trials Market Segmentation By End-User: Pharmaceutical & Biotechnology Companies and Medical Device Companies AI in Clinical Trials Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World
Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Which MedTech key players in the AI in clinical trials market are set to emerge as the trendsetter explore @ AI in Clinical Trials Companies
Table of Contents 1 AI in Clinical Trials Market Report Introduction 2 AI in Clinical Trials Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Clinical Trials Market Key Factors Analysis 6 AI in Clinical Trials Market Porter's Five Forces Analysis 7 AI in Clinical Trials Market Layout 8 AI in Clinical Trials Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us
Interested in knowing the AI in clinical trials market by 2032? Click to get a snapshot of the AI in Clinical Trials Market Trends
Related Reports
Artificial Intelligence in Drug Commercialization Market
Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others.
Artificial Intelligence in Precision Medicine Market
Artificial Intelligence in Precision Medicine Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in precision medicine companies, including TEMPUS, GE HealthCare, Qure.ai, Envisionit Deep AI (Pty) Ltd., Avicenna.AI, Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others.
Artificial Intelligence In Drug Discovery Market
Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others.
Artificial Intelligence in Medical Imaging Market
Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others.
Artificial Intelligence in Life Sciences Market
Artificial Intelligence in Life Sciences Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in life sciences companies, including IBM Corporation, Atomwise, Inc., Nuance Communications, Inc., NuMedii, Inc., AiCure LLC, APIXIO, Inc., Insilico Medicine, Inc., Enlitic, Inc., Sensely, Inc., Zebra Medical Vision, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
6 hours ago
- Business Upturn
Key Home Goods Unveils Limited Edition Cutting Board Collection: Where Functional Art Meets Heritage Craftsmanship
DALLAS, June 21, 2025 (GLOBE NEWSWIRE) — Key Home Goods , a design-forward brand rooted in old-world craftsmanship and modern heritage, proudly announces the release of its Signature Collection, a limited-edition series of artisan-crafted end-grain cutting boards and designer charcuterie boards that merge timeless form with everyday function. Key Home Goods Signature Collection houndstooth cutting board. Each piece in the collection is meticulously handcrafted from American hardwoods, finished with a blend of food-safe oils and waxes, and showcases the brand's distinctive proprietary houndstooth patterns, a visual hallmark that has become synonymous with Key Home Goods. With production strictly limited, every board is reserved for those who seek beauty, exclusivity, and purpose in all that they do. At the heart of this launch is Andrew Key, a seventh-generation Texan, fine woodworker, and the founder of Key Home Goods. What began in 2019 as a pair of custom end-grain cutting boards made as wedding gifts for lifelong friends has grown into a full-fledged pursuit of heirloom craftsmanship. 'I never set out to start just another cutting board company,' says Andrew. 'I wanted to create something truly extraordinary, pieces to be cherished, passed down, and appreciated for both their function and elegance.' The Signature Collection represents more than kitchen tools; it's functional art, thoughtfully designed to elevate the rituals of cooking and gathering. Each board is book-matched for visual harmony, then assembled into a composition that's as structurally resilient as it is visually stunning, honoring the heritage of end-grain cutting boards while pioneering new ground in their design. 'Every board is made slowly, with intention,' Andrew explains. 'Owning a Key Home Goods board is an invitation to savor life's richest moments. A centerpiece for gatherings and a canvas for creating memories with those you love. No two are alike, but every one is designed to be the best board you'll ever own, and the last one you'll ever need.' The Signature Collection is available exclusively at , with early access to new releases offered to registered collectors. Each board ships in custom packaging and includes access to the brand's white-glove support and timeless warranty, known as the Timeless Guarantee. Media Contact:Andrew KeyKey Home Goods [email protected]
Business Upturn
6 hours ago
- Business Upturn
New Subsidiary in Mexico: SOUEAST Debuts S06 i-DM, S07, S09, Pushes Advanced New Energy Tech
By GlobeNewswire Published on June 22, 2025, 09:11 IST MEXICO CITY, June 22, 2025 (GLOBE NEWSWIRE) — On June 18, 2025, at the grand brand and products launch ceremony in Centro Citibanamex, Mexico, SOUEAST announced its entry to Mexican market and unveiled three new models, attracting wide attention, signaling a significant breakthrough in SOUEAST's Latin American expansion. SOUEAST, true to the 'EASE YOUR LIFE' philosophy, is dedicated to urban mobility with stylish, comfort, and warm-tech at its core. SOUEAST offers a diverse range of models — including SUVs and sedans — specifically designed for urban youth. (Image 1: SOUEAST Brand Launch in Mexico) Three Prominent Models Debut: Meeting Diverse Mobility NeedsAt this launch ceremony, SOUEAST introduced three urban-focused models with both fuel and hybrid power types as follows: The S06 i-DM, an urban stylish C-class hybrid SUV, focuses on sporty aesthetics and high efficiency. With its hybrid capabilities and outstanding range, its head-turning contemporary design houses advanced hybrid technology, delivering an impressive 114 km pure electric range and a combined range of over 1,000 km when fully fueled, fully meeting the diverse needs of young people for daily commuting and urban traffic congestion in Mexico. It enhances the driving experience with intelligent features including L2 autonomous driving capabilities and comprehensive smart safety systems. (Image 2: SOUEAST S06 i-DM) The S07, an urban intelligent C-class SUV, skillfully combines practicality and style for urban trendy and fun-loving youth. Beyond its stylish design and comfortable interior, it delivers intelligent features including dual 12.3-inch screens, 6-way adjustable driver seat with memory, remote start and full ADAS, offering luxury-grade connectivity and safety. The S09, a flagship smart premium D-class SUV, redefines spacious luxury with its commanding 4,858*1,925*1,780mm dimensions and 2,850mm wheelbase. Its 7-seat version catering specifically to multi-passenger needs. Powered by a robust 2.0T engine, it caters to urban users with its aesthetic design, intelligent driving, and luxurious features, embodying the brand's high standards. (Image 3: SOUEAST S07 and S09) Each model in the lineup embodies SOUEAST's 'STYLISH-COMFORT-WARM TECH' product DNA, seamlessly integrating innovative technology and exceptional quality, to meet diverse urban mobility needs with EASE. Promoting Comprehensive Localized Operations Regarding the long-term development plan for the Mexican market, SOUEAST adheres to the concept of 'In Mexico, For Mexico' and promotes a comprehensive localized business strategy. In terms of network construction, the company plans to establish 40 showrooms by the end of 2025 and expand to 50 in 2026 in Mexico, building a convenient and efficient service network through a standardized service system. On the after-sales front, preparations are underway for a regional spare parts center for Latin America. This facility will ensure 100% parts availability and enable 24-hour delivery, ensuring rapid response to customer service needs. Meanwhile, the company actively promotes the establishment of the Central and South American Research Institute. Centered on localized product development, the institute aims to introduce models that are better aligned with the preferences and needs of Mexico customers. Driving a New Journey in Latin America: Leading the Future of Green Mobility The Mexican subsidiary showcase SOUEAST's firm commitment to the Latin American market, bringing advanced new energy vehicle(NEV) technologies to Mexico. By offering smart, eco-friendly, and diverse mobility solutions for urban youth, SOUEAST is accelerating Mexico's green transition while expanding its global footprint, with plans to introduce more NEV models and reinforce its role in sustainable development worldwide. Since initiating its globalization strategy in 2024, SOUEAST has made continuous strides across key international markets. Following its global debut in Uzbekistan and rapid entry into multiple markets across the Middle East, the successful launch in Mexico marks another milestone in its growing global presence. To date, SOUEAST has entered more than 30 countries and regions, with over 144 sales and service outlets. Looking ahead, the brand aims to expand into more than 80 markets and establish over 2,000 outlets within five years—bringing the EASE Urban Lifestyle to users worldwide. Photos accompanying this announcement are available at: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
11 hours ago
- Business Upturn
Can't Wait for XRP to Hit $10? PFMCrypto Launches 1-Day Cloud Mining Contract With $10 Free Bonus
Farington, England, June 21, 2025 (GLOBE NEWSWIRE) — Despite growing enthusiasm in the XRP community, the long-awaited $10 milestone remains out of reach. XRP continues to fluctuate between $2.05 and $2.33, showing signs of consolidation rather than breakout. In response, PFMCrypto has introduced a new 1-day XRP cloud mining contract, providing holders with a smart and simple way to generate daily income—even as they wait for the next major price surge. New users receive a $10 signup bonus, enabling them to start mining XRP with no upfront investment. Explore the future of XRP mining now at: One-Day Contract, Same-Day Rewards Unlike traditional mining that relies on expensive hardware and technical know-how, PFMCrypto's XRP cloud mining model is fully remote and designed to simulate yield through proprietary infrastructure and AI-driven optimization. The newly launched 1-day mining contract is the most accessible option yet, letting users activate a plan using their $10 welcome bonus and receive $0.66 in daily XRP rewards—with no cost, no setup, and no risk. This short-term mining model allows XRP holders to earn predictable returns while staying engaged during sideways markets. Key Features of PFMCrypto's XRP Cloud Mining Contracts – No Hardware Required: Accessible to all users without the need for mining equipment or technical setup – Daily Payouts: Earn mining rewards daily based on your contract participation – Secure Custody: Assets are protected under PFMCrypto's industry-grade security standards – Flexible Contract Durations: Choose from short-, mid-, or long-term options to match your investment strategy Flexible Plans for All Investors PFMCrypto offers over 10 unique mining contracts to suit every investor profile—from curious beginners to seasoned holders seeking high-yield options: $10 Contract – 1 Day – Earn $0.66 (free with signup bonus) $100 Contract – 2 Days – Earn $3.00 daily + $2 bonus payout $1,000 Contract – 9 Days – Earn $13.10 daily $5,000 Contract – 30 Days – Earn $78.50 daily For long-term XRP holders, these plans offer a practical way to remain active in the ecosystem and generate steady returns while the token builds momentum toward higher price targets. Click here to explore the $10 XRP mining contract. What Sets PFMCrypto's XRP Mining Contracts Apart? – 100% Remote Access: No equipment, no tech skills—just log in and activate your plan – Capital Protection: Contracts guarantee full principal return upon maturity – AI-Powered Profitability: Yield optimization ensures profitability even during price stagnation – Daily Rewards: Predictable XRP payouts improve cash flow and reduce volatility risk How to Start Mining on PFMCrypto Register an Account: Get a $10 bonus plus $0.66 daily login rewards Select a Mining Contract: Activate a plan using your bonus or choose your own Start Mining: Sit back and earn—rewards are credited daily, automatically A Smarter Way to Wait: Income While XRP Consolidates Founded in 2018, PFMCrypto has been at the forefront of cloud-based crypto mining, democratizing access to passive income through secure, AI-powered, and environmentally conscious infrastructure. The platform is built to help users mine leading cryptocurrencies—like XRP, BTC, SOL, and DOGE—without the need for expensive rigs or in-depth technical knowledge. 'The path to $10 may take time, but XRP holders shouldn't have to wait empty-handed, ' said a PFMCrypto spokesperson. ' Our 1-day mining contracts are designed to give users a simple, low-risk opportunity to generate daily XRP returns—while staying engaged with the ecosystem.' Don't wait for the next rally to start earning—activate your XRP mining contract today at Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
